The expression of the cytoskeletal focal adhesion protein paxillin in breast cancer correlates with HER2 overexpression and may help predict response to chemotherapy: A retrospective immunohistochemical study

Breast Journal

Volumn 13, Issue 2, 2007, Pages 130-139

  Short, Sarah M ^a   Yoder, Brian J ^a   Tarr, Shannon M ^a   Prescott, Nichole L ^a   Laniauskas, Simas ^a   Coleman, Kara A ^a   Downs Kelly, Erinn ^a   Pettay, James D ^a   Choueiri, Toni K ^b   Crowe, Joseph P ^c   Tubbs, Raymond R ^a   Budd, Thomas G ^b   Hicks, David G ^d  

^a Departments of Anatomic and Clinical Pathology L25

^b TAUSSIG CANCER INSTITUTE   (United States)

^c Breast Center/General Surgery A80   (United States)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Breast cancer; Chemotherapy response; HER2; Paxillin; Prognosis

Indexed keywords

CELL ADHESION MOLECULE; CYCLOPHOSPHAMIDE; CYTOSKELETON PROTEIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PAXILLIN; PROGESTERONE RECEPTOR;

ADULT; AGE DISTRIBUTION; ARTICLE; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG RESPONSE; FEMALE; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN SITU HYBRIDIZATION; LYMPH NODE; MAJOR CLINICAL STUDY; PREDICTION; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TUMOR VOLUME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; GENE EXPRESSION; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PAXILLIN; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES;

EID: 33847141029     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/j.1524-4741.2007.00389.x     Document Type: Article

References (50)

1. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. Cancer J Clin 2000;50:7-33.
2. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817-26.
3. Yoder BJ, Tso E, Skacel M, et al. The expression of fascin, an actin-bundling motility protein, correlates with hormone receptor-negative breast cancer and a more aggressive clinical course. Clin Cancer Res 2005;11:186-92.
4. Newell SW, Perchellet JP, Perchellet EM, Ulug ET. Alterations in focal adhesion kinase activity and associated proteins during malignant conversion of mouse keratinocyte. Mol Carcinog 1999;25:73-83.
5. Tang CK, Perez C, Grunt T, et al. Involvement of heregulin-beta2 in the acquisition of the hormone-independent phenotype of breast cancer cells. Cancer Res 1996;56:3350-58.
6. Turner CE. Paxillin interactions. J Cell Sci 2000;113:4139-40.
7. Salgia R, Li JL, Ewaniuk DS, et al. Expression of the focal adhesion protein paxillin in lung cancer and its relation to cell motility. Oncogene 1999;8:67-77.
8. Sattler M, Pisick E, Morrison PT, Salgia R. Role of the cytoskeletal protein paxillin in oncogenesis. Crit Rev Oncog 2000;11:63-76.
9. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12.
10. Vadlamudi R, Adam L, Tseng B, Costa L, Kumar R. Transcriptional up-regulation of paxillin expression by heregulin in human breast cancer cells. Cancer Res 1999;59:2843-46.
11. Davis W, Esteva F, Rajan R, et al. Paxillin overexpression: a reporter of HER-2/neu activity that predicts response to docetaxel/ herceptin™ chemotherapy. Lab Invest 2004;84:s28 (abstract).
12. Tubbs R, Pettay J, Hicks D, et al. Novel bright field molecular morphology methods for detection of HER2 gene amplification. J. Molec. Histol 2004;35:589-94.
13. Yoder B, Choueiri T, Downs-Kelly E. EnzMet GenePro, a novel bright fieldassay that simultaneously profiles HER2 genotype and phenotype, correlates with overall and disease free survival of breast cancer. Mod Pathol 2005;18:s247 (abstract).
14. Downs-Kelly E, Pettay J, Hicks D, et al. Analytical validation and interobserver reproducibility of enzmet genepro: a second-generation bright-field metallography assay for concomitant detection of HER2 gene status and protein expression in invasive carcinoma of the breast. Am J Surg Pathol 2005;29:1505-11.
15. Vadlamudi RK, Adam L, Nguyen D, Santos M, Kumar R. Differential regulation of components of the focal adhesion complex by heregulin: role of phosphatase SHP-2. J Cell Physiol 2002;190:189-99.
16. Ross JS, Fletcher JA, Bloom KJ, et al. Targeted therapy in breast cancer: the HER-2/neu gene and protein. Mol Cell Proteomics 2004;3:379-98.
17. Jukkola A, Bloigu R, Soini Y, et al. c-erbB-2 positivity is a factor for poor prognosis in breast cancer and poor response to hormonal or chemotherapy treatment in advanced disease. Eur J Cancer 2001;37:347-54.
18. Carlomagno C, Perrone F, Gallo C, et al. c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 1996;14:2702-8.
19. Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/ or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001;19:3808-16.
20. Mass R. The role of HER-2 expression in predicting response to therapy in breast cancer. Semin Oncol 2000;27:92-100.
21. Di Leo A, Chan S, Paesmans M, et al. HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Breast Cancer Res Treat 2004;86:197-206.
22. Toikkanen S, Helin H, Isola J, Joensuu H. Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. J Clin Oncol 1992;10:1044-48.
23. Paik S, Bryant J, Park C, et al. erbb-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl. Cancer Inst 1998;90:1361-70.
24. Konecny GE, Thomssen C, Luck HJ, et al. Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. J Natl. Cancer Inst 2004;96:1141-51.
25. Thor AD, Berry DA, Budman DR, et al. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl. Cancer Inst 1998;90:1346-60.
26. Di Leo A, Gancberg D, Larsimont D, et al. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated with an anthracycline-based therapy or with cyclo phosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res 2002;8:1107-16.
27. Jarvinen TA, Tanner M, Rantanen V, et al. Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 2000;156:839-47.
28. Jarvinen TA, Holli K, Kuukasjarvi T, Isola JJ. Predictive value of topoisomerase II alpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer. Br J Cancer 1998;77:2267-73.
29. Paik S, Bryant J, Tan-Chiu E, et al. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Natl. Cancer Inst 2000; 92:1991-98.
30. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl. Acad Sci USA 2001;98:10,869-74.
31. Aas T, Borresen AL, Geisler S, et al. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 1996;2:811-14.
32. Lowe SW, Bodis S, McClatchey A, et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994;266:807-10.
33. Yuminamochi T, Yatomi Y, Osada M, et al. Expression of the LIM proteins paxillin and Hic-5 in human tissues. J Histochem Cytochem 2003;51:513-21.
34. Schaller MD. Paxillin: a focal adhesion-associated adaptor protein. Oncogene 2001;20:6459-72.
35. Brown MC, Turner CE. Paxillin: adapting to change. Physiol Rev 2004;84:1315-39.
36. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992;69:11-25.
37. Subauste MC, Pertz O, Adamson ED, Turner CE, Junger S, Hahn KM. Vinculin modulation of paxillin-FAK interactions regulates ERK to control survival and motility. J Cell Biol 2004;165:371-81.
38. Burridge K, Turner CE, Romer LH. Tyrosine phosphorylation of paxillin and pp125FAK accompanies cell adhesion to extracellular matrix: a role in cytoskeletal assembly. J Cell Biol 1992;119:893-903.
39. Abbi S, Guan JL. Focal adhesion kinase: protein interactions and cellular functions. Histol Histopathol 2002;17:1163-671.
40. Parsons JT. Focal adhesion kinase: the first ten years. J Cell Sci 2003;116:1409-16.
41. Livasy CA, Moore D, Cance WG, Lininger RA. Focal adhesion kinase overexpression in endometrial neoplasia. Appl Immunohistochem Mol Morphol 2004;12:342-45.
42. Owens LV, Xu L, Craven RJ, et al. Overexpression of the focal adhesion kinase (p125FAK) in invasive human tumors. Cancer Res 1995;55:2752-55.
43. Cance WG, Harris JE, Iacocca MV, et al. Immunohistochemical analyses of focal adhesion kinase expression in benign and malignant human breast and colon tissues: correlation with preinvasive and invasive phenotypes. Clin Cancer Res 2000;6:2417-23.
44. Judson PL, He X, Cance WG, Van Le L. Overexpression of focal adhesion kinase, a protein tyrosine kinase, in ovarian carcinoma. Cancer 1999;86:1551-56.
45. Hecker TP, Gladson CL. Focal adhesion kinase in cancer. Front Biosci 2003;8:705-14.
46. Agochiya M, Brunton VG, Owens DW, et al. Increased dosage and amplification of the focal adhesion kinase gene in human cancer cells. Oncogene 1999;18:5646-53.
47. Tong X, Salgia R, Li JL, Griffin JD, Howley PM. The bovine papillomavirus E6 protein binds to the LD motif repeats of paxillin and blocks its interaction with vinculin and the focal adhesion kinase. J Biol Chem 1997;272:33,373-76.
48. Vande Pol SB, Brown MC, Turner CE. Association of Bovine Papillomavirus Type 1 E6 oncoprotein with the focal adhesion protein paxillin through a conserved protein interaction motif. Oncogene 1998;16:43-52.
49. Tremblay L, Hauck W, Aprikian AG, Begin LR, Chapdelaine A, Chevalier S. Focal adhesion kinase (pp125FAK) expression, activation and association with paxillin and p50CSK in human metastatic prostate carcinoma. Int J Cancer 1996;68:164-71.
50. Jenq W, Cooper DR, Ramirez G. Integrin expression on cell adhesion function and up-regulation of P125FAK and paxillin in metastatic renal carcinoma cells. Connect Tissue Res 1996;34:161-74.